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BRIEF COMMUNICATIONS
FATAL INTRAOPERATIVE PULMONARY THROMBOSIS AFTER GRAFT REPLACEMENT OF AN
ANEURYSM OF THE ARCH AND DESCENDING AORTA IN ASSOCIATION WITH DEEP
HYPOTHERMIC CIRCULATORY ARREST AND APROTININ THERAPY
John M. Alvarez, FRACS,a Jacob Goldstein, FRACS,a J. Mezzatesta, FANZCA,b B. Flanagan, FANZCA,b and
M. Dodd, FACBS,c Melbourne, Australia
A 69-year-old woman had graft replacement of the
distal aortic arch and proximal descending thoracic aorta
for a 13 cm atherosclerotic aneurysm. Left ventricular
function and coronary artery anatomy were normal, as
were results of all preoperative hematologic and coagula-
tion assays.
Heparin administration was 300 units/kg plus 5000 units
in the pump prime. Kaolin-based activated clotting time
(ACT) was kept above 500 seconds during cardiopulmo-
nary bypass (CPB) and above 750 seconds before circula-
tory arrest. Protamine was reversed on a 1 mg/100 units
heparin ratio (Table I). Aprotinin (Trasylol) was given for
a total dose of 6 3 106 kallikrein inactivation units (KIU;
2 3 106 KIU intravenously after anesthetic induction, 2 3
106 KIU in the pump prime, and 0.5 3 106 KIU/hr).
After establishment of CPB, antegrade and retrograde
blood cardioplegic arrest together at 18° C, with continu-
ous retrograde cerebral sanguineous perfusion through
the superior vena cava during the period of circulatory
arrest, were employed. The aneurysm was resected and
replaced with a woven polyethylene terephthalate fiber
(Dacron) graft; the arch vessels were reimplanted as a
Carrel patch.
The patient was weaned from CPB unaided, with
normal hemodynamic indexes, effective myocardial con-
tractility, and a dry operative field. Ten minutes later,
unheralded right ventricular failure with a normal elec-
trocardiogram occurred. Protamine was discontinued and
heparin was readministered to the patient. Despite ino-
tropic support and intraaortic balloon counterpulsation,
cardiac function was inadequate. CPB was recommenced,
and right ventricular failure frustrated attempts to discon-
tinue CPB. Transesophageal echocardiography revealed
no valvular abnormality, with effective biventricular con-
traction in the decompressed heart. The pulmonary artery
was opened, yet no evidence of pulmonary embolism was
demonstrable. Right ventricular assistance was com-
menced. Unexplained intermittent inadequate venous re-
turn and raised pulmonary pressures hampered effective
right ventricular assistance action, and the patient died 70
minutes later.
Postmortem examination revealed extensive deposits of
skeinlike, fibrinous material loosely adherent to the walls
of the main and segmental pulmonary arteries, right
ventricle, and within the venous cannulas. Histologic
examination revealed extensive thrombosis within the
small pulmonary artery branches. No evidence of throm-
bosis was detected in other organs.
Aprotinin is highly effective in reducing blood loss after
cardiac operations. However, safety concerns, initially
raised by the Cleveland Clinic group,1 remain unan-
swered. The safety of aprotinin in the setting of aortic
reconstruction with deep hypothermic circulatory arrest is
currently unclear.
Sundt and associates2 from St. Louis and Westaby’s
group from Oxford3 have reported a detrimental effect of
aprotinin in this setting of complex aortic operations with
deep hypothermic circulatory arrest. The St. Louis group
found a higher operative mortality rate, perioperative
myocardial infarction rate, and renal failure rate in the
aprotinin group than in a historical case-matched control
group (15% vs 0%, 20% vs 0%, and 65% vs 5%, respec-
tively).2 The Oxford group reported a greater incidence of
bleeding and thrombosis-related deaths associated with
aprotinin.3
These reports represent large series by experienced
Table I. Case data
Age (yr) 69
Weight (kg) 65
Total dose of heparin (units) 40,000
Total dose of protamine (mg) 400
CPB time (min) 240




Immediately before DHCA 999
Immediately after DHCA 732
After termination of CPB 309
DHCA, Deep hypothermia and circulatory arrest.
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operators. Inadvertent underheparinization in these two
groups has been proposed as a possible explanation by
Smith and associates,4 because the diatomaceous earth
(Celite)–based ACT used in these two series is spuriously
raised in the presence of aprotinin. Westaby and cowork-
ers3 point out that this vital information was not available
when aprotinin (Trasylol) was released into the market-
place.
Goldstein and colleagues5 recently reported their expe-
rience with aprotinin use in this specific group of patients;
they found no differences from a historical case-matched
control group in operative mortality and perioperative
myocardial infarction rates. Renal dysfunction was more
common in the aprotinin group (29.2% vs 8.3%), but not
significantly so (no p value was given). In the series of
Goldstein and colleagues,5 kaolin-based ACT (aprotinin
does not affect this measurement) was kept above 500
seconds and Celite-based ACT was maintained above 750
seconds. Their conclusions are totally at odds with those
of Sundt and coworkers2 and Westaby and colleagues.3
In our case, kaolin-based ACT was used and kept within
accepted guidelines. It is noteworthy that the St. Louis
group encountered a similar case of acute right ventricular
failure from pulmonary thrombosis or embolism. This
case is the only other such complication ever reported
with this type of operation. In this case, no evidence of
preoperative venous thrombosis was present at autopsy.
We firmly believe that this patient was not underhepa-
rinized.
Is aprotinin safe? We concur with Westaby and cowork-
ers3 in saying that we do not know. Only a prospective
randomized trial will yield the answer. Does it actually
produce a benefit? In the series of Goldstein and col-
leagues,5 there was no benefit in terms of total transfusion
requirements. Unless aprotinin results in significantly
fewer patients needing blood transfusions and fewer
transfusions per patient, differences in volume of drainage
and number or type of blood products used are relatively
unimportant.
This case strongly implicates aprotinin use in intravas-
cular thrombosis; acute pulmonary thrombosis in this
setting is extremely rare. This patient was not underhepa-
rinized, nor had she any known coagulation diathesis. Is
this so surprising? Put simply, we do not know what
aprotinin’s physiologic role is, how it works, or how much
to give—or even when the best time to give it is. What we
do know is that it sure does work; is it surprising when it
works too well? To quote Voltaire, “We use drugs about
which we know very little in patients in whom we know
even less.”
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CONCENTRIC LEFT VENTRICULAR HYPERTROPHY LATE AFTER AORTIC VALVE REPLACEMENT
IN TAKAYASU’S ARTERITIS
Yasushi Terada, MD,a Toshio Mitsui, MD,a Yasuhiko Wanibuchi, MD,b Ikutarou Kigawa, MD,b
Sachito Fukuda, MD,b Tomoaki Jikuya, MD,a and Kenji Okamura, MD,a Tsukuba and Tokyo, Japan
The clinical features of aortic regurgitation in Takaya-
su’s arteritis differ from those in other rheumatic or
degenerative valve diseases. In addition to the inflamma-
tory vascular lesions, ventricular arrhythmias occur more
often, and concentric left ventricular hypertrophy occurs
even in the presence of aortic regurgitation.1 The geom-
etry of the left ventricle after aortic valve replacement
(AVR) for Takayasu’s arteritis is unknown and was the
focus of this study.
Patients and methods. Until 1997, 10 female and three
male patients aged 34 to 68 years (mean age 49 years)
underwent AVR for aortic regurgitation in Takayasu’s
arteritis. There were multiple vascular lesions. AVR was
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